Oculis Holding
OCS
7 hedge funds and large institutions have $44.3M invested in Oculis Holding in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 4 closing their positions.
38% more capital invested
Capital invested by funds: $32.1M → $44.3M (+$12.2M)
2.93% more ownership
Funds ownership: 8.02% → 10.95% (+2.9%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
22% less funds holding
Funds holding: 9 → 7 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$15.1M |
| 2 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
+$319K |
| 3 |
SC
Searle & Co
Greenwich,
Connecticut
|
+$104K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
-$3.42M |
| 2 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
-$911K |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$77.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$22K |
| 5 |
EC
Elequin Capital
New York
|
-$3.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PBPIA
1
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
| $21.2M | -$3.42M | -329,966 | -15% |
|
|
2
Aberdeen Group
Edinburgh,
United Kingdom
| $16M | +$15.1M | +1,452,741 | New |
|
|
NFGH
3
Nan Fung Group Holdings
Kai Tak,
Hong Kong
| $5.83M | -$911K | -87,751 | -14% |
|
|
CLOS
4
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
| $1.05M | +$319K | +30,750 | +47% |
|
|
5
Bank of America
Charlotte,
North Carolina
| $190K | +$1.14K | +110 | +0.7% |
|
|
SC
6
Searle & Co
Greenwich,
Connecticut
| $11K | +$104K | +10,000 | New |
|
|
DCM
7
Dupont Capital Management
Wilmington,
Delaware
| $44 | – | – | – |
|
|
WAM
8
Wolverine Asset Management
Chicago,
Illinois
| – | -$77.2K | -7,021 | Closed |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$22K | -2,002 | Closed |
|
|
EC
10
Elequin Capital
New York
| – | -$3.3K | -300 | Closed |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| – | -$2.24K | -204 | Closed |
|
OCS Hedge Fund Activity: Q4 2023 in Review
7 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Oculis Holding (OCS) for Q4 2023, worth a combined $44.3M — up 38% from $32.1M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of OCS and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Aberdeen Group, opening a new position worth an estimated $15.1M. The largest seller was Pivotal bioVenture Partners Investment Advisor, cutting an estimated $3.42M.
- 7 institutional investors held Oculis Holding (OCS) as of Q4 2023, down from 9 in Q3 2023.
- Funds reported $44.3M of Oculis Holding stock for Q4 2023, up 38% quarter-over-quarter.
- 2 funds opened new Oculis Holding positions in Q4 2023 and 4 closed out, a net change of -2 holders.
- The largest Oculis Holding buyer in Q4 2023 was Aberdeen Group, an estimated $15.1M added.
- The largest Oculis Holding seller in Q4 2023 was Pivotal bioVenture Partners Investment Advisor, an estimated $3.42M sold.
Based on aggregated 13F filings for Q4 2023.